MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
OPKO Health Net Debt 2011-2026 | OPK
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -411 M | -75.2 M | -132 M | 82.2 M | 163 M | 184 M | 108 M | 55.3 M | -73.5 M | -58.1 M | 50.4 M | 41.9 M | -4.68 M | -62.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 184 M | -411 M | -9.48 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
1.24 B | $ 120.47 | 1.2 % | $ 36.6 B |  USA |
 |
Anixa Biosciences
ANIX
|
-1.04 M | $ 2.9 | 2.47 % | $ 94.1 K | USA |
 |
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-76 M | $ 22.13 | -5.98 % | $ 243 M |  China |
 |
Celcuity
CELC
|
82.8 M | $ 108.86 | 1.36 % | $ 4.29 B | USA |
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
-108 M | $ 27.97 | 1.43 % | $ 777 M | USA |
 |
Fulgent Genetics
FLGT
|
-53.3 M | $ 14.17 | 2.72 % | $ 428 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M |  Britain |
 |
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
Charles River Laboratories International
CRL
|
1.98 B | $ 179.12 | 1.95 % | $ 8.88 B | USA |
 |
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
IDEXX Laboratories
IDXX
|
222 M | $ 638.42 | 0.62 % | $ 51.3 B | USA |
 |
Illumina
ILMN
|
-494 M | $ 131.73 | 1.67 % | $ 20.9 B | USA |
 |
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
4.74 B | $ 282.44 | -0.19 % | $ 23.5 B | USA |
 |
Lantheus Holdings
LNTH
|
213 M | $ 79.34 | 0.63 % | $ 5.35 B | USA |
 |
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K |  Israel |
|
Biodesix
BDSX
|
14.5 M | $ 15.04 | -2.97 % | $ 1.95 B | USA |
 |
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Mettler-Toledo International
MTD
|
2.06 B | $ 1 319.33 | 0.2 % | $ 27.2 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
115 M | $ 5.43 | 2.65 % | $ 503 M | USA |
 |
Invitae Corporation
NVTA
|
-239 M | - | - | $ 21.2 M | USA |
 |
NeoGenomics
NEO
|
187 M | $ 9.65 | 1.1 % | $ 1.24 B | USA |
 |
BioNano Genomics
BNGO
|
-2.64 M | $ 1.12 | - | $ 1.42 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
4.92 B | $ 209.29 | 0.44 % | $ 23.2 B | USA |
 |
Danaher Corporation
DHR
|
14 B | $ 204.98 | 0.48 % | $ 146 B | USA |
 |
National Research Corporation
NRC
|
30.1 M | $ 13.39 | - | $ 329 M | USA |
 |
Organovo Holdings
ONVO
|
-10.4 M | - | -2.3 % | $ 19.4 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-916 M | $ 103.46 | 0.09 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
334 M | $ 8.57 | -1.95 % | $ 537 M | USA |
 |
DarioHealth Corp.
DRIO
|
-12.1 M | $ 10.5 | 1.94 % | $ 298 M | Israel |
 |
DexCom
DXCM
|
-842 M | $ 71.55 | -2.09 % | $ 27.9 B | USA |
 |
PerkinElmer
PKI
|
2.3 B | - | -0.91 % | $ 14.7 B | USA |
 |
Pacific Biosciences of California
PACB
|
-6.67 M | $ 1.62 | 6.25 % | $ 486 M | USA |
 |
Psychemedics Corporation
PMD
|
-3.41 M | - | -1.84 % | $ 15.3 M | USA |
 |
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B |  Niderland |
 |
ICON Public Limited Company
ICLR
|
4.63 B | $ 111.03 | 2.14 % | $ 9.16 B |  Irlanda |
 |
Quotient Limited
QTNT
|
103 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Precipio
PRPO
|
-1.18 M | $ 25.4 | 1.7 % | $ 33 M | USA |
 |
Renalytix AI plc
RNLX
|
24.5 K | - | 5.66 % | $ 22.7 M | Britain |
 |
CareDx, Inc
CDNA
|
-39.2 M | $ 19.2 | 2.13 % | $ 1.02 B | USA |
 |
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | USA |